Liposomal Bupivacaine Versus Bupivacaine Plain for Operative Pain Management of Forefoot Surgery
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Prospective, randomized, controlled single-blinded trial comparing liposomal bupivacaine with
bupivacaine HCl for postoperative management. Upon completion of the forefoot procedure in
the operative room the subject will be entered into the randomization system which will
specify whether to inject 10cc (5mg/mL) of bupivacaine HCl or 8cc (13.3 mg/mL) liposomal
bupivacaine, both considered routine care procedure. Thereafter, postoperative pain will be
assessed and measured using a Visual Analog Scale (VAS) scoring scale post-operatively at 2
hours, 24 hours, 48 hours and 72 hours. In addition, the amount of oral morphine equivalents
(OME) required postoperatively and time to first use of OME will be measured. Our hypothesis
is that patients who received liposomal bupivacaine will have less post-operative pain and
require less OMEs.